G-CSF Receptor Inhibition for Acute Respiratory Distress Syndrome

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Despite decades of research, there is a high mortality rate associated with acute respiratory distress syndrome (ARDS) due to a lack of effective pharmacological therapies, and current treatments primarily rely on supportive care.

Innovation Solution

Inhibiting granulocyte colony stimulating factor (G-CSF) signaling using compounds that bind to the G-CSF receptor (G-CSFR) to reduce lung inflammation in ARDS.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If supportive therapies (oxygenation, mechanical ventilation, fluid management) are used to treat ARDS, then patient survival is maintained, but mortality rate remains high due to lack of effective pharmacological intervention

Engineering Contradiction:

Improvepatient survivalVSAvoidavailability of effective pharmacological therapy

Core Design Contradiction:

ReliabilityVSEase of manufacture

Solution Approach 1:

The patent extracts and targets the specific pathological mechanism (G-CSF signaling pathway) driving ARDS progression. By isolating this key inflammatory pathway from the complex disease process, the invention enables targeted pharmacological intervention using anti-G-CSF antibodies, moving beyond non-specific supportive care to mechanism-based therapy that directly addresses the root cause of lung inflammation and injury in ARDS

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The invention changes the therapeutic parameter from non-specific supportive measures to specific molecular targeting. By administering anti-G-CSF antibodies that bind to and neutralize the G-CSF cytokine, the treatment modifies the inflammatory response parameters directly, reducing neutrophil recruitment and activation in the lungs, thereby improving outcomes in ARDS patients

Inventive Principle:

Principle #35Parameter changes

2Object-affected harmful factors

If G-CSF signaling is inhibited to reduce lung inflammation, then ARDS severity is reduced, but potential side effects on neutrophil function may occur

Engineering Contradiction:

Improvelung inflammationVSAvoidneutrophil function

Core Design Contradiction:

Object-affected harmful factorsVSReliability

Solution Approach 1:

The patent applies preliminary action by administering the anti-G-CSF antibody at the onset or early stages of ARDS development. This timing allows the antibody to prevent excessive neutrophil recruitment and activation before significant lung injury occurs, thereby reducing inflammation while maintaining neutrophil function for normal host defense. The early intervention prevents the harmful cascade rather than attempting to reverse established damage

Inventive Principle:

Principle #10Preliminary action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The method effectively reduces lung inflammation and severity of ARDS, potentially preventing the onset of ARDS and reducing the need for mechanical ventilation and other intensive care interventions.

Implementation Method 1

an antibody which binds to G-CSF receptor (G-CSFR) and inhibits G-CSF signaling

Methodology Applied

Scientific EffectAntibody binding:

Data Source

PatentUS12583929B2Method of treating acute respiratory distress syndrome

Publication Date: 2026.03.24 CSL LIMITED

AI summary

The present disclosure relates to methods of treating or preventing acute respiratory distress syndrome (ARDS) using compounds that inhibit G-CSF signaling. The present disclosure also relates to compounds for use in the treatment or prevention of ARDS, as well as the use of such compounds in the manufacture of medicaments for the treatment or prevention of ARDS.